AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10932338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ava Neb 1780 (output 205 +/- 13 mg/min)
Number of subjects: 27
Study 10932338 — intervention group
Group type: COMPARATOR
Intervention: Hudson UP Draft II 1730 (output 356 +/- 31 mg/min)
Number of subjects: 27
Study 8986486 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine treatment
Number of subjects: 28
Study 8986486 — intervention group
Group type: COMPARATOR
Intervention: Severe sepsis (no norepinephrine)
Number of subjects: 28
Study 1594414 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reinforcement group
Number of subjects: 29
Study 1594414 — intervention group
Group type: EXPERIMENTAL
Intervention: Group given statements of personal importance
Number of subjects: 29
Study 1594414 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 6085804 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B/gramicidin ear drop combination at bedtime on the day they swam
Number of subjects: 1000
Study 6085804 — intervention group
Group type: COMPARATOR
Intervention: Strict rules to prevent water entering the ear (bathing caps, earplugs)
Number of subjects: 1000
Study 31412290 — intervention group
Group type: EXPERIMENTAL
Intervention: Trehalose
Number of subjects: 9
Study 31412290 — intervention group
Group type: COMPARATOR
Intervention: Carboxymethylcellulose (CMC)
Number of subjects: 9
Study 30111683 — intervention group
Group type: EXPERIMENTAL
Intervention: Paprika xanthophyll capsules (9.0 mg of paprika xanthophylls)
Number of subjects: 100
Study 30111683 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 100
Study 27417947 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine with epinephrine
Number of subjects: 11
Study 27417947 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine without epinephrine
Number of subjects: 11
Study 24507417 — intervention group
Group type: EXPERIMENTAL
Intervention: INSPIRED (Individual Support & Resources for Diabetes) Manual with Health Coach support over seven weeks
Number of subjects: 180
Study 24507417 — intervention group
Group type: COMPARATOR
Intervention: Fact sheets containing key information about diabetes self-management
Number of subjects: 180
Study 23135080 — intervention group
Group type: COMPARATOR
Intervention: Superpulse-mode fractional CO2 laser (SPCO2)
Number of subjects: 18
Study 23135080 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapulse-mode fractional CO2 laser (UPCO2)
Number of subjects: 18
Study 20417293 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs with flare design
Number of subjects: 20915
Study 20417293 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs without flare design
Number of subjects: 20915
Study 17951267 — intervention group
Group type: COMPARATOR
Intervention: Standard Approach (SA)
Number of subjects: 198
Study 17951267 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Approach (TA)
Number of subjects: 198
Study 16304442 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dentifrice (1100 microg F/g) after lunch
Number of subjects: 11
Study 16304442 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrice (550 microg F/g) on fasting
Number of subjects: 11
Study 16304442 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 microg F/g)
Number of subjects: 11
Study 12546171 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (90 mL mixed with 300 mL clear liquid and 4-5 glasses of water)
Number of subjects: 100
Study 12546171 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol solution (2 liters)
Number of subjects: 100
Study 11202131 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin 60 mg/day plus fluoxetine 20 mg/day
Number of subjects: 104
Study 11202131 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 104
Study 11202131 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin 60 mg/day
Number of subjects: 104
Study 9458419 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 62
Study 9458419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 8195448 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse
Number of subjects: 18
Study 8195448 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine/0.022% sodium fluoride rinse
Number of subjects: 18
Study 8195448 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine fluoride rinse
Number of subjects: 18
Study 8195448 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 18
Study 2466056 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of pirmenol
Number of subjects: 6
Study 2466056 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of pirmenol
Number of subjects: 6
Study 2466056 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of pirmenol
Number of subjects: 6
Study 2466056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29790382 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ventilation (LV, respiratory rate ≤8/minute and tidal volume <500 mL)
Number of subjects: 60
Study 29790382 — intervention group
Group type: COMPARATOR
Intervention: Standard ventilation (SV)
Number of subjects: 60
Study 26792238 — intervention group
Group type: EXPERIMENTAL
Intervention: Prearrival instructions including the specific location of AEDs
Number of subjects: 39
Study 26792238 — intervention group
Group type: COMPARATOR
Intervention: Control group (no location information provided)
Number of subjects: 39
Study 25709404 — intervention group
Group type: EXPERIMENTAL
Intervention: Viron (three tablets twice daily)
Number of subjects: 82
Study 25709404 — intervention group
Group type: EXPERIMENTAL
Intervention: Viron (two tablets twice daily)
Number of subjects: 82
Study 25709404 — intervention group
Group type: EXPERIMENTAL
Intervention: Viron (one tablet twice daily)
Number of subjects: 82
Study 25709404 — intervention group
Group type: EXPERIMENTAL
Intervention: Viron (highest dose)
Number of subjects: 82
Study 25709404 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 82
Study 23631785 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived peer social support for physical activity
Number of subjects: 434
Study 23631785 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood walkability
Number of subjects: 434
Study 23631785 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 434
Study 20157845 — intervention group
Group type: EXPERIMENTAL
Intervention: Promised incentive of one lottery ticket to be received upon reply
Number of subjects: 450
Study 20157845 — intervention group
Group type: EXPERIMENTAL
Intervention: Promised incentive of one lottery ticket to be received upon reply and an additional lottery ticket upon reply within 1 week
Number of subjects: 450
Study 20157845 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 450
Study 20157845 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response across all groups
Number of subjects: 450
Study 20157845 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of response curves between no incentive and incentive groups
Number of subjects: 450
Study 18254429 — intervention group
Group type: EXPERIMENTAL
Intervention: Model program
Number of subjects: 65
Study 18254429 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 65
Study 17444155 — intervention group
Group type: EXPERIMENTAL
Intervention: Terasosine (setegis) 1 mg twice a day for 2 months
Number of subjects: 36
Study 17444155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12894960 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker intervention (nurse-supervised, trained in blood pressure management)
Number of subjects: 0
Study 12894960 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker intervention (2 different levels of intensity)
Number of subjects: 0
Study 10966997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg taken once every 4 weeks
Number of subjects: 100
Study 10966997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10966997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg
Number of subjects: 100
Study 8864322 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotrophin releasing hormone (TRH) 50 micrograms
Number of subjects: 0
Study 8864322 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotrophin releasing hormone (TRH) 200 micrograms
Number of subjects: 0
Study 8864322 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotrophin releasing hormone (TRH) 500 micrograms
Number of subjects: 0
Study 8864322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglion blocking drug pentolinium (5 mg) with TRH 500 micrograms
Number of subjects: 0
Study 8864322 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-adrenoceptor blockade with thymoxamine (0.3 mg kg-1 bolus + 0.3 mg kg-1 h-1 infusion) with TRH 500 micrograms
Number of subjects: 0
Study 8864322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol (10 mg i.v. over 10 min) with TRH 500 micrograms
Number of subjects: 0
Study 1728909 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated blood pressure monitoring
Number of subjects: 0
Study 1728909 — intervention group
Group type: COMPARATOR
Intervention: Casual office blood pressure measurement
Number of subjects: 0
Study 29786678 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical rehabilitation for in-patients (n=25)
Number of subjects: 135
Study 29786678 — intervention group
Group type: COMPARATOR
Intervention: Personality-oriented program for physical rehabilitation (first group n=45)
Number of subjects: 135
Study 29786678 — intervention group
Group type: COMPARATOR
Intervention: Personality-oriented program for physical rehabilitation (second group n=40)
Number of subjects: 135
Study 27478925 — intervention group
Group type: EXPERIMENTAL
Intervention: Late mealtimes (4.5, 8.5, 14.5 and 16 hours after awakening)
Number of subjects: 4
Study 27478925 — intervention group
Group type: COMPARATOR
Intervention: Normal mealtimes (1, 5, 11 and 12.5 hours after awakening)
Number of subjects: 4
Study 27478925 — intervention group
Group type: EXPERIMENTAL
Intervention: Late sleep/normal meal
Number of subjects: 4
Study 27478925 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sleep/late meal
Number of subjects: 4
Study 27478925 — intervention group
Group type: EXPERIMENTAL
Intervention: Late sleep/late meal
Number of subjects: 4
Study 27478925 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep/normal meal
Number of subjects: 4
Study 23574999 — intervention group
Group type: EXPERIMENTAL
Intervention: Carperitide infusion
Number of subjects: 303
Study 23574999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 22627104 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus oxaliplatin
Number of subjects: 1236
Study 22627104 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil alone
Number of subjects: 1236
Study 20825986 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (up to 400 mg per day, administered twice daily, titrated by 100 mg every 6 months)
Number of subjects: 53
Study 20825986 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 53
Study 18522634 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy
Number of subjects: 0
Study 18522634 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 0
Study 16855464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg up to 100 mg per usage)
Number of subjects: 21
Study 16855464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 14587682 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 20
Study 14587682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11061616 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (450 microg/m2 days 4-5 and 15-16)
Number of subjects: 19
Study 11061616 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (450 microg/m2 days 4-5 and 15-16) plus (225 microg/m2 days 6-10 and 17-21)
Number of subjects: 19
Study 11061616 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (450 microg/m2 days 4-10 and 15-21)
Number of subjects: 19
Study 11061616 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 19
Study 11061616 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing GM-CSF doses
Number of subjects: 19
Study 11061616 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 19
Study 9311404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (2‐min bolus, 100 mg; 15 min infusion, 40 micrograms.kg‐1.min‐1)
Number of subjects: 11
Study 9311404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8320947 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate Hemodialysis (AHD)
Number of subjects: 12
Study 8320947 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate Hemodialysis (BHD)
Number of subjects: 12
Study 8320947 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free Biofiltration (AFB)
Number of subjects: 12
Study 2947606 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethylrutosides (600 mg, four times before smoking)
Number of subjects: 46
Study 2947606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 29533715 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal focus group (INTERNAL)
Number of subjects: 30
Study 29533715 — intervention group
Group type: COMPARATOR
Intervention: External focus group (EXTERNAL)
Number of subjects: 30
Study 27507627 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltration of 0.7 mL 8.4% sodium bicarbonate with 0.3 mL 2% lidocaine containing 1:80,000 epinephrine
Number of subjects: 100
Study 27507627 — intervention group
Group type: COMPARATOR
Intervention: Control group received 0.7 mL sterile distilled water with 0.3 mL 2% lidocaine containing 1:80,000 epinephrine
Number of subjects: 100
Study 24907722 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (86 patients)
Number of subjects: 120
Study 24907722 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous erythropoietin receptor activator (34 patients)
Number of subjects: 120
Study 24907722 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 120
Study 22540433 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (600 mg/day)
Number of subjects: 70
Study 22540433 — intervention group
Group type: COMPARATOR
Intervention: Methadone (60 mg/day)
Number of subjects: 70
Study 20299774 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine suppository (60 mg or 120 mg) + PNB
Number of subjects: 100
Study 20299774 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine gel (10 ml of 2% lidocaine) + PNB
Number of subjects: 100
Study 20299774 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository + PNB
Number of subjects: 100
Study 20299774 — intervention group
Group type: COMPARATOR
Intervention: PNB alone
Number of subjects: 100
Study 19317172 — intervention group
Group type: EXPERIMENTAL
Intervention: Shufeng Liangxue Decoction (SLD)
Number of subjects: 116
Study 19317172 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic Western medical therapy (Control)
Number of subjects: 116
Study 15961159 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional scleral buckling
Number of subjects: 225
Study 15961159 — intervention group
Group type: COMPARATOR
Intervention: Primary vitrectomy
Number of subjects: 225
Study 12912714 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (875 mg amoxicillin and 125 mg clavulanic acid, twice daily for 6 days)
Number of subjects: 252
Study 12912714 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 252
Study 12912714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 10608400 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-BOPTA 0.05 mmol/kg (group A)
Number of subjects: 201
Study 10608400 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-BOPTA 0.1 mmol/kg (group B)
Number of subjects: 201
Study 10608400 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-BOPTA 0.2 mmol/kg (group C)
Number of subjects: 201
Study 10608400 — intervention group
Group type: COMPARATOR
Intervention: Gd-BOPTA (all groups)
Number of subjects: 201
Study 8618198 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (75 mg/kg administered orally)
Number of subjects: 7
Study 8618198 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.2 mg/kg administered intravenously)
Number of subjects: 7
Study 2006346 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural analgesia (TEA) with bupivacaine 0.75% pre- and intraoperatively, followed by bupivacaine 0.25% continuously for 3 days.
Number of subjects: 116
Study 2006346 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural analgesia (TEA) with bupivacaine.
Number of subjects: 116
Study 2006346 — intervention group
Group type: COMPARATOR
Intervention: Balanced anesthesia (isoflurane plus fentanyl) with systemic analgesia on request (piritramide i.m., tramadol, or a simple analgesic).
Number of subjects: 116
Study 6756262 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage Vitamin E treatment (target serum E levels, 5-6 mg/dl)
Number of subjects: 24
Study 6756262 — intervention group
Group type: COMPARATOR
Intervention: Non-Vitamin E treatment (control group)
Number of subjects: 24
Study 6756262 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E treatment from birth (pilot studies, target serum E levels, 1.5 and 3.0 mg/dl)
Number of subjects: 24
Study 6756262 — intervention group
Group type: COMPARATOR
Intervention: Prestudy infants (1968-72) fed early iron supplements and given formulas with low E:PUFA ratios
Number of subjects: 24
Study 31837240 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin
Number of subjects: 264
Study 31837240 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 264
Study 31132015 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively-framed information
Number of subjects: 134
Study 31132015 — intervention group
Group type: COMPARATOR
Intervention: Negatively-framed information
Number of subjects: 134
Study 31132015 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants (following Ice Bucket Challenge)
Number of subjects: 134
Study 28222871 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement
Number of subjects: 20
Study 28222871 — intervention group
Group type: COMPARATOR
Intervention: Self-adhesive resin cement
Number of subjects: 20
Study 26232122 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology Taping (KT) applied over the rectus femoris muscle
Number of subjects: 22
Study 26232122 — intervention group
Group type: COMPARATOR
Intervention: Placebo Taping (PT) using adhesive nonelastic tape over the rectus femoris muscle
Number of subjects: 22
Study 23797459 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth Pursuit Therapy (SPT)
Number of subjects: 50
Study 23797459 — intervention group
Group type: COMPARATOR
Intervention: Visual Scanning Therapy (VST)
Number of subjects: 50
Study 20979013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA) 1 g/10 mL in 20 mL of 5% glucose
Number of subjects: 660
Study 20979013 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30 mL 5% glucose)
Number of subjects: 660
Study 20979013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA)
Number of subjects: 660
Study 19302083 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg daily for 3 days prior to quit date, then 50 mg daily for 8 weeks)
Number of subjects: 78
Study 19302083 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 78
Study 19302083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 19302083 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone and Placebo
Number of subjects: 78
Study 17587398 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 1.0 mg three times daily (t.i.d.)
Number of subjects: 230
Study 17587398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 90 mg three times daily (t.i.d.)
Number of subjects: 230
Study 17587398 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 230
Study 12698086 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free immunosuppression (no steroids)
Number of subjects: 27
Study 12698086 — intervention group
Group type: COMPARATOR
Intervention: Steroid treatment (long-term and short-term)
Number of subjects: 27
Study 10936117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg once daily (qd)
Number of subjects: 253
Study 10936117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg twice daily (bid)
Number of subjects: 253
Study 10936117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (either qd or bid)
Number of subjects: 253
Study 10936117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (both regimens) during 54 weeks of open-label treatment
Number of subjects: 253
Study 10936117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (bid)
Number of subjects: 253
Study 8880273 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Electronic Medical Dossier (EMD)
Number of subjects: 0
Study 1560164 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of inhaled salmeterol
Number of subjects: 12
Study 1560164 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of inhaled salmeterol
Number of subjects: 12
Study 1560164 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of inhaled salbutamol
Number of subjects: 12
Study 1560164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2411079 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg acetylsalicylic acid daily for 24 weeks
Number of subjects: 16